We compare the standard strategy to reduce ovarian cancer risk, i.e. RRSO at recommended age of 35–40 in BRCA1 and at recommended age of 40–45 in BRCA2 mutation carriers, with an innovative risk-reducing strategy. This evidence concerns the gene BRCA1 and ovarian cancer.